GE Healthcare Life Sciences has announced the commercial availability of SpinOculation C-Pro Protocol Software. The launch, the company said, expands flexible solutions across the cell therapy workflow.
"The SpinOculation C-Pro software application automates and simplifies a critical step in the cell therapy workflow and helps accelerate the development of next-generation therapeutics," explained Catarina Flyborg, General Manager, Cell and Gene Therapy, GE Healthcare Life Sciences.
When used in combination with the Sepax C-Pro instrument and CT-60.1 single-use kit, the software enables users to choose the volume and cell concentration from initial cell preparation through transduction to final resuspension, without compromising cell viability and virus stability.
Additionally, the SpinOculation C-Pro Protocol helps user tos:
- Gain reproducibility in transduction steps with an automated and closed solution
- Save time in the manufacturing process by reducing manipulations
- Optimize transduction performance by adjusting open system parameters
- Simplify process validation by not using transduction enhancers
Marine De Lageneste, Development Engineer, R&D, Cell & Gene Therapy will answer questions at the Cell Therapy Manufacturing & Gene Therapy Congress for the poster titled “Closed and automated CAR-T cell lentiviral transduction by spinoculation.’’ The Congress takes place in Amsterdam, the Netherlands from 3-6 December 2019.
